SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Adami HO, Hunter D, Trichopoulos D. Textbook of cancer epidemiology. New York: Oxford University Press, 2002: 400428.
  • 2
    Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in healthcare. Washington, DC: National Academy Press, 2002.
  • 3
    Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute.
  • 4
    Jemal A, Clegg LX, Ward C, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 2004; 101: 327.
  • 5
    Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003; 97: 15071516.
  • 6
    Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (surveillance, epidemiology, and end results) program population-based study. Arch Intern Med. 2002; 162: 19851993.
  • 7
    Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate. 2005; 62: 243252.
  • 8
    Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001; 93: 388395.
  • 9
    Kittles RA, Weiss KM. Race, ancestry, and genes: implications for defining disease risk. Annu Rev Genomics Hum Genet. 2003; 4: 3367.
  • 10
    Bach PB, Schrag D, Brawley OW, et al. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 21062113.
  • 11
    Jemal A, Ward E, Wu X, et al. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev. 2005; 14: 590595.
  • 12
    Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002; 94: 334357.
  • 13
    Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med. 2003; 18: 845853.
  • 14
    Shavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004; 19: 146155.
  • 15
    Underwood W 3rd, Wei J, Rubin MA, et al. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urol Oncol. 2004; 22: 2024.
  • 16
    Underwood W 3rd, Jackson J, Wei JT, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992–1999. Cancer. 2005; 103: 538545.
  • 17
    Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004; 64: 11711176.
  • 18
    Peters N, Armstrong K. Racial differences in prostate cancer treatment outcomes: a systematic review. Cancer Nurs. 2005; 28: 108118.
  • 19
    Polednak AP. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc. 1998; 90: 101104.
  • 20
    Howard G, Anderson RT, Russell G, Howard VJ, Burke GL. Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol. 2000; 10: 214223.
  • 21
    Tarman GJ, Kane CJ, Moul JW, et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology. 2000; 56: 10161020.
  • 22
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 7893.
  • 23
    Neal RD, Allgar VL. Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the ‘National Survey of NHS Patients: Cancer’. Br J Cancer. 2005: 92: 19711975.
  • 24
    Bach PB, Pham HH, Schrag D, Tate RC, Hargrave JL. Primary care physicians who treat blacks and whites. N Engl J Med. 2004; 351: 575584.
  • 25
    Potosky AL, Riley GF, Lubitz JD, Mentnech RN, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732748.
  • 26
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40(8 Suppl ): IV3IV18.
  • 27
    Mandelblatt JS, Kerner JF, Hadley J, et al. Variations in breast carcinoma treatment in older Medicare beneficiaries: is it black or white. Cancer. 2002; 95: 14011414.
  • 28
    Robert SA, Strombom I, Trentham-Dietz A, et al. Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology. 2004; 15: 442450.
  • 29
    Du XL, Chan W, Giordano S, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 2005; 104: 913924.
  • 30
    National Cancer Institute. SEER-Medicare linked database. Bethesda, MD: NCI, 2004.
  • 31
    National Cancer Institute. The SEER program code manual. NIH Publication No. 94-1999. Bethesda, MD: NIH, 1994.
  • 32
    U.S. Public Health Services. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Los Angeles, CA: PMIC, 1996.
  • 33
    American Medical Association. Physicians' Current Procedural Terminology-CPT 2000. Chicago, IL, 2000.
  • 34
    Du XL, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol. 1999; 52: 463470.
  • 35
    Health Care Financing Administration. HCFA Common Procedure Coding System: National Level II Medicare Codes. Los Angeles, CA: PMIC, 2000.
  • 36
    Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001; 19: 14551461.
  • 37
    Allison PD. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995.
  • 38
    Kleinbaum DG. Survival analysis: a self-learning text. New York: Springer, 1996.
  • 39
    Polednak AP. Black-white differences in survival from late-stage prostate cancer. Ethn Dis. 2003; 13: 220225.
  • 40
    U.S. Department of Health and Human Services. Healthy People 2010: understanding and improving health. Washington, DC: US Government Printing Office, November 2000.
  • 41
    Patel KV, Eschbach K, Ray LA, Markides, KS. Evaluation of mortality data for older Mexican Americans: implications for the Hispanic paradox. Am J Epidemiol. 2004; 159: 707715.
  • 42
    Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997; 349: 906910.
  • 43
    Du XL, Key CR, Dickie L, Darling R, Geraci JM, Zhang D. External validation of Medicare claims for breast cancer chemotherapy compared to medical chart reviews. Med Care. 2006; 44: 124131.
  • 44
    Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr., Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 20612067.